GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Shiller PE Ratio

Insmed (Insmed) Shiller PE Ratio : (As of May. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Insmed Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Insmed Shiller PE Ratio Historical Data

The historical data trend for Insmed's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Shiller PE Ratio Chart

Insmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insmed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Insmed's Shiller PE Ratio

For the Biotechnology subindustry, Insmed's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Insmed's Shiller PE Ratio falls into.



Insmed Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Insmed's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Insmed's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.06/131.7762*131.7762
=-1.060

Current CPI (Mar. 2024) = 131.7762.

Insmed Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.590 100.560 -0.773
201409 -0.540 100.428 -0.709
201412 -0.360 99.070 -0.479
201503 -0.550 99.621 -0.728
201506 -0.470 100.684 -0.615
201509 -0.500 100.392 -0.656
201512 -0.510 99.792 -0.673
201603 -0.540 100.470 -0.708
201606 -0.590 101.688 -0.765
201609 -0.610 101.861 -0.789
201612 -1.100 101.863 -1.423
201703 -0.600 102.862 -0.769
201706 -0.720 103.349 -0.918
201709 -0.690 104.136 -0.873
201712 -0.850 104.011 -1.077
201803 -0.890 105.290 -1.114
201806 -1.000 106.317 -1.239
201809 -1.140 106.507 -1.410
201812 -1.190 105.998 -1.479
201903 -0.960 107.251 -1.180
201906 -0.810 108.070 -0.988
201909 -0.680 108.329 -0.827
201912 -0.590 108.420 -0.717
202003 -0.740 108.902 -0.895
202006 -0.640 108.767 -0.775
202009 -0.630 109.815 -0.756
202012 -1.000 109.897 -1.199
202103 -0.890 111.754 -1.049
202106 -1.070 114.631 -1.230
202109 -0.960 115.734 -1.093
202112 -0.950 117.630 -1.064
202203 -0.800 121.301 -0.869
202206 -0.800 125.017 -0.843
202209 -1.090 125.227 -1.147
202212 -1.210 125.222 -1.273
202303 -1.170 127.348 -1.211
202306 -1.780 128.729 -1.822
202309 -1.110 129.860 -1.126
202312 -1.280 129.419 -1.303
202403 -1.060 131.776 -1.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Insmed  (NAS:INSM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Insmed Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Insmed's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed (Insmed) Business Description

Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Executives
Flammer Martina M.d. officer: Chief Medical Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett officer: Chief Commercial Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise officer: Chief Commercial Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith officer: General Counsel, Senior VP 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis officer: President & CEO 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole officer: Chief People Strategy Officer INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano officer: Chief Compliance Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari officer: General Counsel & Secretary 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807